It has been over a century since Carlos Chagas discovered the Trypanosoma cruzi (T. cruzi)
as the causative agent of Chagas disease (CD), a neglected tropical disease with several …

Background: The American trypanosomiasis, Chagas disease, is a parasitic infection
typically spread by triatomine vectors affecting millions of people all over Latin America …

Oxidative stress is involved in several parasitic diseases such as Chagas. Agents able to
selectively modulate biochemical processes involved in the disease represent promising …

Two series of new 5-nitroindazole derivatives, 1-substituted 2-benzylindazolin-3-ones (6–
29, series A) and 3-alkoxy-2-benzyl-2H-indazoles (30–37, series B), containing differently …

Indazole is a vital nitrogen-containing heterocyclic unit in organic and medicinal chemistry
research and a helpful precursor molecule for the production of various types of …

The development of new compounds to treat Chagas disease is imperative due to the
adverse effects of current drugs and their low efficacy in the chronic phase. This study aims …

Chagas disease is a prevalent health problem in Latin America which has received
insufficient attention worldwide. Current treatments for this disease, benznidazole and …

For years, Chagas disease treatment has been limited to only two drugs of highly
questionable and controversial use (Nifurtimox® and Benznidazole®). In the search of …

Trypanosoma cruzi is the etiological agent of Chagas disease. Epimastigote forms of T. cruzi
can be readily cultured in axenic conditions. Ethanol and dimethyl sulfoxide (DMSO) are …

Benznidazole is the first-line drug used in treating Chagas disease, which is caused by the
parasite Trypanosoma cruzi (T. cruzi). However, benznidazole has limited efficacy and …